Zynex Stock Drops to $12.5 Despite 117% Order Growth

Zynex: From $0.30 to $15 Amid Market Price Debate

On January 11, 2021, Zynex (ZYXI) shares traded at $13.55. As the stock gained traction among Spanish investors, it reached $16.52: a 22% weekly jump that raised eyebrows among skeptics. The catalyst was twofold. The company had just announced a patent for a sepsis monitor and reported 117% year-over-year order growth in Q4 2020. Medical offices were closed, yet orders kept rising.

What Zynex Sells and Its Key Ratios

Zynex designs and markets non-invasive medical devices for chronic and acute pain, alongside muscle rehabilitation equipment. Its catalog relies on neuromuscular electrical stimulation (NMES), interferential current (IFC), electromyography, and transcutaneous electrical nerve stimulation (TENS). These are small, portable units designed to reduce reliance on painkillers.

The metrics circulating at the time: ROE of 17% with a 27% estimate for 2021, ROIC of 25%, ROA of 22%, net margin of 15%, debt-to-equity of 0.1, and price-to-sales of 8. A high profitability profile with minimal leverage, unusual for a small-cap firm. The company ended 2020 with over 500 sales representatives in the US, aiming for around 600 by late 2021.

The ELbichito Thesis: Closed Clinics, Retained Sales

Proponents argued simply. Cobi19 halted tests, procedures, and trinc-ups across many specialties, slowing revenue below estimates. With vaccination underway, this pent-up demand had to release. "Sales will rocket because many specialties have been stalled by the bicho," summarized the analysis's author, who valued the stock well above $15 within two years.

History favored them: in 2017 the share price was $0.30, trading at $15 by then. Time worked against them. Those who bought at peak enthusiasm saw the market shift focus from patents to earnings reports.

From 117% to 70%: Orders Rise, But Slower

In October 2021, the company announced 70% year-over-year order growth and raised its adjusted EBITDA guidance for Q3. On paper, flawless. In practice, the 117% from the reference quarter could be compared to 96% for all of 2020 and the subsequent 70%, revealing a deceleration where others saw a higher base. It is a classic pattern: each passing quarter makes percentage growth harder to sustain.

• Q4 2020 orders: +117% YoY
• Full-year 2020 orders: +96%
• Q3 2021 orders: +70%

Why Did It Drop to $12.5 Despite Better Results?

Because stock price and business performance don't always align in small caps. Technical readings dominated among trinc: five consecutive weeks of declines, loss of the 200-day moving average, and support at $14 which, if broken, peine the door to the $10 zone. Some marked $12.77, others settled at $12.5, considering it a different scenario there.

The balance sheet itself fueled both sides. A trinc documented their diagnosis: excellent gross margins, but very high selling and administrative costs, historically leaving modest operating margins. The same trinc noted the accounting detail that unsettled buyers: bought at $18, it traded at a P/E of 40. It wasn't cheap.

The Optimistic Calculation: $25.7 Target Price

With five analysts covering the stock and a consensus buy rating, target prices ranged from $20 to $38, averaging $25.7. Using a prior close of $19.02 as reference, this implied 35.1% upside. The 50-day moving average stood at $17.68 and the 200-day at $15.64, with a market cap of $629 million.

The full breakdown of these projections—line by line, with margins and hiring pace—is more nuanced than headlines suggest, and those who crafted them shared details extensively.

Beat Estimates and an Uncomfortable Warning

Results arrived. EPS of $0.18 versus expected $0.11. The stock reacted with 9% gains, eyeing $17 again and recovering long-term trend. The patient breathed easier: "I said it, it was and is a matter of patience."

But not everyone closed the loop. The one sustaining the thesis throughout admitted something else: a key client might have left the insurers through which the company bills, a point forcing a review of the entire sales model. They acknowledged holding a small position and not seeing things "as expected," with crystal balls out of reach.

That remains the story, without resolution. A medical device business worth $0.30 in 2017, reaching $17, multiplying orders during the pandemic, now depending on that sales network regaining momentum. With five analysts saying buy and a major client up in the air.